Pre-IND Meeting Strategy: Making the Most of Your FDA Interaction

Of all the regulatory interactions available to a biologics developer before IND filing, the Pre-IND meeting is the most underutilized and the most valuable. Done well, it gives you written FDA feedback on your development program before you commit to GMP manufacturing — feedback that can reshape your CMC strategy, sharpen your analytical package, and substantially reduce the probability of a clinical hold. Done poorly, it is a missed opportunity that no amount of post-hoc remediation fully replaces.

What a Pre-IND Meeting Is — and Is Not

A Pre-IND meeting (formally, a Type B meeting under FDA's PDUFA meeting management framework) is an opportunity to present your development program to FDA reviewers before the IND is filed and to obtain written feedback that can shape your CMC, pharmacology/toxicology, and clinical development strategy. It is not a negotiation or an approval.

FDA responses at Pre-IND stage are advisory and non-binding. That said, thoughtful engagement at Pre-IND stage almost always reduces the probability of clinical hold at IND filing and helps align your development program with FDA's current thinking on issues specific to your molecule's class, mechanism of action, or manufacturing approach.

The Pre-IND meeting is, ultimately, a free editorial review of your development strategy by the people who will approve your drug. Treat it accordingly.

How to Request a Pre-IND Meeting and What to Submit

A Pre-IND meeting request is submitted to the appropriate FDA center — CDER for most biologics, CBER for vaccines, blood products, and gene and cellular therapies — along with a meeting request package. For CDER biologics, the request is directed to the relevant Division based on therapeutic area, and the package must include a briefing document describing the drug substance, the proposed indication, the nonclinical program, and the specific questions for which you are seeking FDA input.

Key procedural timelines to plan around:

• FDA has 21 days to respond to a Type B meeting request with a meeting date
• The meeting typically occurs within 70 days of the request
• Your briefing document should be submitted at least 30 days before the meeting date
• FDA provides written responses to your questions either at the meeting or within 30 days after

The meeting request package itself should be concise — typically 10–20 pages — and focused. A sprawling briefing document that covers every aspect of your program at equal depth is harder for reviewers to engage with than one that clearly frames the program and then zeroes in on the specific open questions where FDA input is most needed.

Structuring Your CMC Questions Effectively

The CMC section of a Pre-IND briefing document is where CDMO partners can add the most value. Effective CMC questions for a biologics Pre-IND typically address:

• The acceptability of your proposed manufacturing platform and scale for Phase 1
• Your proposed strategy for demonstrating monoclonality and whether it meets current expectations
• The acceptability of your reference standard strategy if you are using non-GMP material for initial characterization
• Your proposed analytical methods for release and their qualification status at IND filing
• The agency's current expectations for process-related impurity acceptance criteria — particularly HCP and residual DNA — for your specific molecule type and patient population

The last point is particularly important if your molecule targets a pediatric or immunocompromised population, where residual impurity thresholds may be applied more conservatively than the standard WHO guidance values. Asking FDA directly what they expect for your patient population — and getting the answer in writing before you set specifications — is far more efficient than discovering the gap during IND review.

Using Pre-IND Feedback to Strengthen Your IND Filing

The real return on investment from a Pre-IND meeting is realized when the feedback is systematically incorporated into your IND CMC section. Each written FDA response to a CMC question should be treated as a structural requirement for the corresponding section of your filing.

If FDA indicates that your proposed HCP acceptance criterion is at the high end of what they would expect, that is a signal to either tighten the criterion with a process optimization plan, or to provide a more detailed safety justification. If FDA notes that your scale-down model qualification approach has not been clearly described, that is a direct prompt to add a dedicated section in Module 3 of your IND explaining SDM qualification. If FDA asks a clarifying question in their written response, treat it as advance notice of an information request — answer it in your IND before they ask again.

Sponsors who treat Pre-IND feedback as such — preparing precise questions, incorporating feedback systematically, and using the written responses to structure their IND — consistently experience fewer information requests and clinical holds than those who treat Pre-IND feedback as advisory noise.